Clinical pharmacokinetics of tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Clinical pharmacokinetics of tyrosine kinase inhibitors

Published:2009-12 Issue:8 Volume:35 Page:692-706
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

van Erp Nielka P.,Gelderblom Hans,Guchelaar Henk-Jan

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference163 articles.

1. A minute chromosome in human chronic granulocytic leukemia;Nowell;Science,1960

2. DNA contents of chromosome PH1 and chromosome 21 in human chronic granulocytic leukemia;Rudkin;Science,1964

3. Aproposed standard system of nomenclature of human mitotic chromosomes;Lejeune;Lancet,1960

4. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining;Rowley;Nature,1973

5. Quantification by DNA-based cytophotometry of the 9q+/22q-chromosomal translocation associated with chronic myelogenous leukemia;Mayall;Cancer Res,1977

Cited by 373 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization and optimization of magnetic molecularly imprinted nanofibers for determination of sunitinib in human serum and capsule samples;Talanta;2024-11

2. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08

3. Drug-drug interactions between tyrosine kinase inhibitors and concomitance medications: Drug safety in cancer treatment;Tạp Chí Khoa Học Trường Đại Học Quốc Tế Hồng Bàng;2024-06-24

4. Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 4: Experimental validation of the models of drug concentration in blood;International Journal of Pharmaceutics;2024-06

5. Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 3: Theoretical models of drug concentration in blood;International Journal of Pharmaceutics;2024-06